Skip to main content
Industry News
GSK, Vir to expand trial for COVID-19 antibody treatment

GlaxoSmithKline and collaborator Vir Biotechnology aim to widen the scope of the trial for their experimental antibody as a treatment for COVID-19 after no safety concerns were raised in the first 20 volunteers. The expanded trial will have half of the 1,300 participants randomly assigned to receive a placebo, with interim trial results expected to become available possibly by year's end and complete efficacy results slated to be released by within the first quarter of next year.

Full Story: